If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today - Krystal Biotech ( NASDAQ:KRYS )
Krystal Biotech KRYS has outperformed the market over the past 5 years by 12.38% on an annualized basis producing an average annual return of 26.0%. Currently, Krystal Biotech has a market capitalization of $4.32 billion.
Quoin ( QNRX ) Q2 Loss Beats Estimates
Quoin Pharmaceuticals ( NASDAQ:QNRX ) , a clinical-stage biotech focused on rare dermatological diseases, announced its second quarter 2025 results on August 7, 2025. The highlight was a net loss per American Depositary Share ( ADS ) of $ ( 6.28 ) ( GAAP ) , which beat the consensus GAAP estimate ...
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook
Krystal Biotech tops Q2 estimates with strong Vyjuvek sales, but shares fall 14% on weak Q3 revenue guidance.
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results - CommScope Holding Co ( NASDAQ:COMM ) , BT Brands ( NASDAQ:BTBD )
U.S. stocks traded higher midway through trading, with the S&P 500 gaining more than 1% on Monday. The Dow traded up 1.27% to 44,141.11 while the NASDAQ climbed 1.82% to 21,026.44. The S&P 500 also rose, gaining, 1.37% to 6,323.33. Communication services shares jumped by 2.3% on Monday.
Krystal ( KRYS ) Q2 Profit Jumps 143%
Krystal Biotech ( NASDAQ:KRYS ) , a gene therapy company specialized in rare skin and genetic diseases, reported its latest quarterly results on August 4, 2025, for the second quarter of fiscal 2025. The company posted better-than-expected financials, reporting GAAP earnings per share of $1.29 ...
Krystal Biotech, Inc. ( KRYS ) Tops Q2 Earnings and Revenue Estimates
Krystal Biotech (KRYS) delivered earnings and revenue surprises of +19.44% and +6.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today - Krystal Biotech ( NASDAQ:KRYS )
Krystal Biotech KRYS has outperformed the market over the past 5 years by 15.6% on an annualized basis producing an average annual return of 29.57%. Currently, Krystal Biotech has a market capitalization of $4.43 billion.
Tango Therapeutics, Inc. ( TNGX ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Tango Therapeutics (TNGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025 - Krystal Biotech ( NASDAQ:KRYS )
PITTSBURGH, July 29, 2025 ( GLOBE NEWSWIRE ) -- Krystal Biotech, Inc. ( the "Company" ) KRYS, a commercial-stage biotechnology company, today announced that it will report its second quarter 2025 financial results on Monday, August 4, 2025, prior to the open of U.S. markets.
Krystal Biotech, Inc. ( KRYS ) to Report Q2 Results: Wall Street Expects Earnings Growth
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family ...
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
KB304 designed to deliver collagen and elastin to restore skin naturally ...
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Krystal Biotech ( NASDAQ:KRYS )
Krystal Biotech KRYS has outperformed the market over the past 5 years by 15.76% on an annualized basis producing an average annual return of 29.85%. Currently, Krystal Biotech has a market capitalization of $4.34 billion.
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye ...
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Krystal Biotech ( NASDAQ:KRYS )
Krystal Biotech KRYS has outperformed the market over the past 5 years by 13.21% on an annualized basis producing an average annual return of 28.0%. Currently, Krystal Biotech has a market capitalization of $4.13 billion.
Catherine Mazzacco Takes A Bullish Stance, Acquiring Krystal Biotech Stock Options Worth $6K - Krystal Biotech ( NASDAQ:KRYS )
A notable acquisition unfolded on June 30, as Mazzacco, Director at Krystal Biotech KRYS, reported the acquisition of stock options for 5,000 shares in an SEC filing. What Happened: In a recent Form 4 filing with the U.S.
Dino A Rossi Exhibits Confidence With An Acquisition Of Krystal Biotech Stock Options Worth $6K - Krystal Biotech ( NASDAQ:KRYS )
Dino A Rossi, Board Member at Krystal Biotech KRYS, reported acquisition of company stock options on June 30, according to a new SEC filing. What Happened: Revealed in a Form 4 filing on Monday with the U.S.
Insider Decision Unfolding At Krystal Biotech: Christopher Mason Exercises Options, Resulting In $0 - Krystal Biotech ( NASDAQ:KRYS )
A substantial insider activity was disclosed on June 30, as Mason, Board Member at Krystal Biotech KRYS, reported the exercise of a large sell of company stock options. What Happened: In an insider options sale disclosed in a Form 4 filing on Monday with the U.S.
Notable Insider Move: Daniel Janney Takes Part In Options Exercise At Krystal Biotech, Resulting In $0 - Krystal Biotech ( NASDAQ:KRYS )
Highlighted on June 30, it was unveiled in an SEC filing that Janney, Director at Krystal Biotech KRYS, executed a significant transaction involving the exercise of company stock options. What Happened: A Form 4 filing from the U.S.
Breaking Update: Everett Rand Sutherland Engages In Options Exercise At Krystal Biotech Realizing $0 - Krystal Biotech ( NASDAQ:KRYS )
A large exercise of company stock options by Everett Rand Sutherland, Board Member at Krystal Biotech KRYS was disclosed in a new SEC filing on June 30, as part of an insider exercise. What Happened: Disclosed in a Form 4 filing on Monday with the U.S.
Julian S Gangolli Takes A Bullish Stance, Acquiring Krystal Biotech Stock Options Worth $6K - Krystal Biotech ( NASDAQ:KRYS )
Disclosed in a recent SEC filing, Julian S Gangolli, Director at Krystal Biotech KRYS, made a strategic move by acquiring company stock options on June 30,. What Happened: In a Form 4 filing with the U.S.
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global ...
3 Promising Genomics Stocks to Keep an Eye On in 2025
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study
Krystal Biotech rises 4% after dosing begins in a phase III study of KB803 eye drops to treat rare DEB-related corneal damage.
Strength Seen in Krystal Biotech ( KRYS ) : Can Its 4.2% Jump Turn into More Strength?
Krystal Biotech (KRYS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa - Krystal Biotech ( NASDAQ:KRYS )
Intra-patient, double-blind, multicenter, placebo-controlled study with crossover design Repeat administration under compassionate use was previously shown to be well tolerated and associated with full corneal healing by 3 months as well as significant visual acuity improvement from hand motion ...
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
Intra-patient, double-blind, multicenter, placebo-controlled study with crossover design ...
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Krystal Biotech ( NASDAQ:KRYS )
Krystal Biotech KRYS has outperformed the market over the past 5 years by 10.14% on an annualized basis producing an average annual return of 23.9%. Currently, Krystal Biotech has a market capitalization of $3.84 billion.
Why Is Krystal Biotech ( KRYS ) Down 3.5% Since Last Earnings Report?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Implied Volatility Surging for Krystal Biotech Stock Options
Investors need to pay close attention to KRYS stock based on the movements in the options market lately.
What Does the Market Think About Krystal Biotech? - Krystal Biotech ( NASDAQ:KRYS )
Krystal Biotech's KRYS short percent of float has risen 9.9% since its last report. The company recently reported that it has 2.60 million shares sold short, which is 15.1% of all regular shares that are available for trading.
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Krystal Biotech ( NASDAQ:KRYS )
Krystal Biotech KRYS has outperformed the market over the past 5 years by 5.72% on an annualized basis producing an average annual return of 19.46%. Currently, Krystal Biotech has a market capitalization of $3.61 billion.
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today - Krystal Biotech ( NASDAQ:KRYS )
Krystal Biotech KRYS has outperformed the market over the past 5 years by 2.98% on an annualized basis producing an average annual return of 17.49%. Currently, Krystal Biotech has a market capitalization of $3.82 billion.
Krystal Biotech to Present at BofA Securities 2025 Health Care Conference
PITTSBURGH, May 07, 2025 ( GLOBE NEWSWIRE ) -- Krystal Biotech, Inc. ( the "Company" ) ( NASDAQ: KRYS ) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. Krish S.
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down
KRYS reports disappointing first-quarter 2025 results, with both earnings and sales missing estimates. Shares down.
Krystal Biotech, Inc. ( KRYS ) Misses Q1 Earnings and Revenue Estimates
Krystal Biotech (KRYS) delivered earnings and revenue surprises of -13.04% and 6.69%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Intellia Therapeutics, Inc. ( NTLA ) Q1 Earnings Expected to Decline
Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease - Abeona Therapeutics ( NASDAQ:ABEO )
Zevaskyn's list price set at $3.1 million; 2025 revenue forecast raised to $31.6 million. Analyst projects U.S. peak sales of $600 million with 750 potential RDEB patients. Don't face extreme market conditions unprepared.
Krystal Biotech, Inc. ( KRYS ) Earnings Expected to Grow: Should You Buy?
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Krystal Biotech ( NASDAQ:KRYS )
Krystal Biotech KRYS has outperformed the market over the past 5 years by 15.4% on an annualized basis producing an average annual return of 29.66%. Currently, Krystal Biotech has a market capitalization of $4.89 billion.
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - Krystal Biotech ( NASDAQ:KRYS )
VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
VYJUVEK approved for the treatment of DEB from birth in Europe ...
Krystal Biotech to Present at Upcoming Scientific Conferences
PITTSBURGH, April 24, 2025 ( GLOBE NEWSWIRE ) -- Krystal Biotech, Inc. ( the "Company" ) ( NASDAQ: KRYS ) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and June.
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.
Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025
PITTSBURGH, April 17, 2025 ( GLOBE NEWSWIRE ) -- Krystal Biotech, Inc. ( the "Company" ) ( NASDAQ: KRYS ) , a commercial-stage biotechnology company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 6, 2025, prior to the open of U.S. markets.
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag
The FDA bestows a Regenerative Medicine Advanced Therapy tag on FATE's pipeline candidate, FT819, for treating moderate-to-severe systemic lupus erythematosus.
Ironwood Shares Tank on Regulatory Update for Apraglutide
Per the latest discussion with the FDA, a confirmatory phase III study is required to seek approval for IRWD's apraglutide in short bowel syndrome with intestinal failure.
Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe
The European Commission approves RHHBY's Columvi combo to treat adult patients with diffuse large B-cell lymphoma after initial therapy.
